Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients-A Proof of Concept

Monitoring measurable residual disease (MRD) is crucial to assess treatment response in Multiple Myeloma (MM). Detection of MRD in peripheral blood (PB) by exploring Extracellular Vesicles (EVs), and their cargo, would allow frequent and minimally invasive monitoring of MM. This work aims to detect...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-11, Vol.23 (22), p.13686
Main Authors: Bergantim, Rui, Peixoto da Silva, Sara, Polónia, Bárbara, Barbosa, Mélanie A G, Albergaria, André, Lima, Jorge, Caires, Hugo R, Guimarães, José E, Vasconcelos, M Helena
Format: Article
Language:English
Subjects:
Biomarkers
Biomarkers - metabolism
Biopsy
Blood
Cancer therapies
Clinical trials
Communication
Disease
Drug resistance
Extracellular vesicles
Extracellular Vesicles - metabolism
Humans
Liquid Biopsy
Medical prognosis
Monitoring
Monoclonal antibodies
Morphology
Multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - metabolism
Neoplasm, Residual - diagnosis
Patients
Peripheral blood
Plasma
Proteins
Remission
Remission (Medicine)
Size exclusion chromatography
Telemedicine
Tomography
Ultrafiltration
Vesicles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Monitoring measurable residual disease (MRD) is crucial to assess treatment response in Multiple Myeloma (MM). Detection of MRD in peripheral blood (PB) by exploring Extracellular Vesicles (EVs), and their cargo, would allow frequent and minimally invasive monitoring of MM. This work aims to detect biomarkers of MRD in EVs isolated from MM patient samples at diagnosis and remission and compare the MRD-associated content between BM and PB EVs. EVs were isolated by size-exclusion chromatography, concentrated by ultrafiltration, and characterized according to their size and concentration, morphology, protein concentration, and the presence of EV-associated protein markers. EVs from healthy blood donors were used as controls. It was possible to isolate EVs from PB and BM carrying MM markers. Diagnostic samples had different levels of MM markers between PB and BM paired samples, but no differences between PB and BM were found at remission. EVs concentration was lower in the PB of healthy controls than of patients, and MM markers were mostly not detected in EVs from controls. This study pinpoints the potential of PB EVs from MM remission patients as a source of MM biomarkers and as a non-invasive approach for monitoring MRD.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms232213686